Retroviral transduction of a mutant dihydrofolate reductase-thymidylate synthase fusion gene into murine marrow cells confers resistance to both methotrexate and 5-fluorouracil

Human Gene Therapy

Volumn 14, Issue 5, 2003, Pages 435-446

  Capiaux, Gina M ^a,b   Budak Alpdogan, Tulin ^b   Takebe, Naoko ^b,d   Mayer Kuckuk, Philipp ^b   Banerjee, Debabrata ^b   Maley, Frank ^c   Bertino, Joseph R ^a,b,e  

^a Weill Cornell Graduate School of Biomedical Sciences   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c WADSWORTH CENTER   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROFOLATE REDUCTASE; FLUOROURACIL; HYBRID PROTEIN; METHOTREXATE; THYMIDYLATE SYNTHASE;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CELL KINETICS; COLON CANCER; CONTROLLED STUDY; ENZYME KINETICS; FUSION GENE; GENE FUNCTION; GENE MUTATION; GENE TRANSFER; GENETIC TRANSDUCTION; HEMATOPOIETIC STEM CELL; HUMAN; NONHUMAN; PROTEIN EXPRESSION; RETROVIRUS; TOXICITY; VIRAL GENE THERAPY;

3T3 CELLS; ANIMALS; BLOTTING, WESTERN; BONE MARROW CELLS; CELL SURVIVAL; CELLS, CULTURED; DRUG RESISTANCE; FLUOROURACIL; GENE EXPRESSION; GENETIC VECTORS; MALE; METHOTREXATE; MICE; MICE, INBRED C57BL; MUTATION; PROTEIN BIOSYNTHESIS; RECOMBINANT FUSION PROTEINS; RETROVIRIDAE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TETRAHYDROFOLATE DEHYDROGENASE; THYMIDYLATE SYNTHASE; TRANSDUCTION, GENETIC;

ANIMALIA; MURINAE; UNIDENTIFIED RETROVIRUS;

EID: 0037457015     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/104303403321467207     Document Type: Article

References (53)

1. ALLAY, J.A., PERSONS, D.A., GALIPEAU, J., RIBERDY, J.M., ASHMUN, R.A., BLAKLEY, R.L., and SORRENTINO, B.P. (1998). In vivo selection of retrovirally transduced hematopoietic stem cells. Nat. Med. 4, 1136-1143.
2. BAUM, C., OSTERTAG, W., STOCKING, C., and VON LAER, D. (2002). Retroviral vector design for cancer gene therapy. In: Gene Therapy of Cancer: Translational Approaches from Preclinical Studies to Clinical Implementation 2nd ed. E. Lattime, S. Gerson, eds. (Academic Press, San Diego, CA) pp. 3-29.
3. BERTINO, J.R. (1997). Biomodulation of 5-Fluorouracil with antifolates. Semin. Oncol. 24, S18-52-S18-56.
4. BLAKELY, R.L. (1984). Dihydrofolate reductase. In Folates and Pteridines. Vol. 1. R.L. Blakely, S.J. Benkovic, eds. (Wiley, New York) pp. 191-253.
5. BONADONNA, G., ZAMBETTI, M., and VALAGUSSA, P. (1995). Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than 3 positive nodes. 10 year results. JAMA 273, 542-547.
6. BRADFORD, M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 21, 179-189.
7. CASH, J.M., and KLIPPEL, J.H. (1994). Second-line drug therapy for rheumatoid arthritis. N. Engl. J. Med. 330, 1368-1375.
8. CHALLITA, P.M., and KOHN, D.B. (1994). Lack of expression from a retroviral vector after transduction of murine hematopoietic stem cells is associated with methylation in vivo. Proc. Natl. Acad. Sci. U.S.A. 91, 2567-2571.
9. CHALLITA, P.M., SKELTON, D., EL-KHOUEIRY, A., YU, X.J., WEINBERG, K., and KOHN, D.B., (1995). Multiple modifications in cis elements of the long terminal repeat of retroviral vectors lead to increased expression and decreased DNA methylation in embryonic carcimoma cells. J. Virol. 69, 748-755.
10. CHU, E., and ALLEGRA, C.J. (1996). Antifolates. In: Cancer Chemotherapy and Biotherapy, 2nd ed. B.A Chabner and D.L. Longo, eds. (Lippincott-Raven Publishers, Philadelphia), pp. 109-148.
11. CHUNDURU, S.K., CODY, V., LUFT, J.R., PANGBORN, W., APPLEMAN, J.R., and BLAKLEY, R.L. (1994). Methotrexate-resistant variants of human dihydrofolate reductase. Effects of Phe-31 substitutions. J. Biol. Chem. 269, 9547-9555.
12. CITRON, M., BERRY, D., CIRRINCIONE, C., CARPENTER, J., HUDIS, C., GRADISHAR, W., DAVIDSON, N., INGLE, J., MARTINO, S., LIVINGSTON, R., WINER, E., MUSS, H., and NORTON, L. (2002). Superiority of dose-dense (DD) over conventional scheduling (CS) and equivalence of sequential (SC) vs. combination adjuvant chemotherapy (CC) for node-positive breast cancer. Abstract 15, 25th Annual San Antonio Breast Cancer Symposium.
13. COUTRE, L.A., MULLEN, C.A., and MORGAN, R.A. (1994). Retroviral vectors containing chimeric promoter/enhancer elements exhibit cell-type-specific gene expression. Hum. Gene Ther. 5, 667-677.
14. DE MULDER, P.H. (1999). The chemotherapy of head and neck cancer. Anticancer Drugs 10, S33-37.
15. DUGGLEBY, R.G. (1984). Regression analysis of nonlinear Arrhenius plots: An empirical model and a computer program. Comput. Biol. Med. 14, 447-455.
16. DUNN, S.M.J., and KING, R.W. (1980). Kinetics of ternary complex formation between dihydrofolate reductase, coenzyme and inhibitor. Biochemistry 19, 766-773.
17. ELLIS, K.J., and MORRISON, J.F. (1982). Buffers of constant ionic strength for studying pH dependent processes. Methods Enzymol. 87, 405-426.
18. ERCIKAN-ABALI, E.A., MINEISHI, S., TONG, Y., NAKAHARA, S., WALTHAM, M.C., BANERJEE, D., CHEN, W., SADELAIN, M., and BERTINO, JR. (1996a). Active site-directed double mutants of dihydrofolate reductase. Cancer Res. 56, 4142-4145.
19. ERCIKAN-ABALI, E.A., WALTHAM, M.C., DICKER, A.P., SCHWEITZER, B.I., GRITSMAN, H., BANERJEE, D., and BERTINO, J.R. (1996b). Variants of human dihydrofolate reductase with substitutions at leucine-25: Effect on catalytic and inhibitor binding properties. Mol. Pharmacol. 49, 430-437.
20. FANTZ, C.R., SHAW, D., MOORE, J.G., and SPENCER, H.T. (1998). Retroviral coexpression of thymidylate synthase and dihydrofolate reductase confers fluoropyrimidine and antifolate resistance. Biochem. Biophys. Res. Commun. 243, 6-12.
21. FERONE, R., and ROLAND, S. (1980). Dihydrofolate reductase: Thymidylate synthase, a bifunctional polypeptide from Crithidia fasciculata. Proc. Natl. Acad. Sci. U.S.A. 77, 5802-5806.
22. GARRETT, C.E., CODERRE, J.A., MEEK, T.D., GARVEY, E.P., CLAMAN, D.M., BEVERLEY, S.M., and SANTI, D.V. (1984). A bifunctional thymidylate synthetase-dihydrofolate reductase in protozoa. Mol. Biochem. Parasitol. 11, 257-265.
23. HILLCOAT, B.L., NIXON. P.F., and BLAKELY, R.L. (1967). Effect of substrate decomposition on the spectrophotometric assay of dihydrofolate reductase. Anal. Biochem. 21, 179-189.
24. HUGHEY, C.T., BARBOUR, K.W., BERGER, F.G., and BERGER, S.H. (1993). Functional effects of a naturally occurring amino acid substitution in human thymidylate synthase. Mol. Pharmacol. 44, 316-323.
25. IWAKURA, M., and KOKUBU, T. (1995). Production of heterodimeric dihydrofolate reductase-thymidylate synthase bifunctional enzyme. J. Biochem. (Tokyo) 118, 67-74.
26. KISLIUK, R.L. (2000). Synergistic interactions among antifolates. Pharmacol. Ther. 85, 183-190.
27. KLUG, C.A., CHESHIER, S., and WEISSMAN, I.L. (2000). Inactivation of a GFP retrovirus occurs at multiple levels in long-term repopulating stem cells and their differentiated progeny. Blood 96, 894-901.
28. LEWIS, W.S., CODY, V., GALITSKY, N., LUFT, J.R., PANGBORN, W., CHUNDURU, S.K., SPENCER, H.T., APPLEMAN, J.R., and BLAKELY, R.L. (1995). Methotrexate-resistant variants of human dihydrofolate reductase with substitutions of leucine 22. Kinetics, crystallography, and potential as selectable markers. J. Biol. Chem. 270, 5057-5064.
29. MARKOWITZ, D., GOFF, S., and BAND, A. (1988). Construction and use of a safe and efficient amphotropic packaging cell line. Virology 167, 400-406.
30. MAY, C., GUNTHER, R., and MCIVOR, R. S. (1995). Protection of Mice from lethal doses of methotrexate by transplantation with transgenic marrow expressing drug-resistant dihydrofolate reductase activity. Blood 86, 2439-2448.
31. MAYER-KUCKUK, P., BANERJEE, D., MALHOTRA, S., DOUBROVIN, M., IWAMOTO, M., AKHURST, T., BALATONI, J., BORNMANN, W., FINN, R., LARSON, S., FONG, Y., GELOVANI TJUVAJEV, J., BLASBERG, R., and BERTINO, J.R. (2002). Cells exposed to antifolates show increased cellular levels of proteins fused to dihydrofolate reductase: A method to modulate gene expression. Proc. Natl. Acad. Sci. U.S.A. 99, 3400-3405.
32. MODER, K.G., TEFFERI, A., COHEN, M.D., MENKE, D.M., and LUTHRA, H.S. (1995). Hematologic malignancies and the use of methotrexate in rheumatoid arthritis: A retrospective study. Am. J. Med. 99, 276-282.
33. NAKANO, T., SPENCER, T., APPLEMAN, J.R., and BLAKELY, R.L. (1994). Critical role of phenylalanine 34 of human dihydrofolate reductase in substrate and inhibitor binding and catalysis. Biochemistry 33, 9945-9952.
34. NIELSEN, E. and CELLA, R. (1988). Thymidylate synthase in plant cells: Kinetic and molecular properties of the enzyme from Daucus carota L. cell cultures. Plant Cell Physiol. 29, 503-508.
35. NILSSON, S.K., DOONER, M.S., TIARKS, C.Y., WEIER, H.U., and QUESENBERRY, P.J. (1997). Potential and distribution of transplanted hematopoietic stem cells in a nonablated mouse model. Blood 89, 4013-4020.
36. NORDIC GASTROINTESTINAL TUMOR ADJUVANT THERAPY GROUP. (1989). Superiority of sequential methotrexate, fluorouracil, and leucovorin to fluorouracil alone in advanced symptomatic colorectal carcinoma: A randomized trial. J. Clin. Oncol. 7, 1437-1446.
37. PEDERSEN-LANE, J., MALEY, G.F., CHU, E., and MALEY, F. (1997). High-level expression of human thymidylate synthase. Prot. Exp. Purif. 10, 256-262.
38. SANTI, D.V., and DANENBERG, P.V. (1984). Chemistry and biochemistry of folates. In Folates and Pteridines. Vol. 1. R.L. Blakely, S.J. Benkovic, eds. (Wiley, New York) pp. 343-396.
39. SAUERBREY, A., MCPHERSON, J.P., ZHAO, S., BANERJEE, D., and BERTINO, J.R. (1999). Expression of a novel double-mutant dihydrofolate reductase-cytidine deaminase fusion gene confers resistance to both methotrexate and cytosine arabinoside. Hum. Gene Ther. 10, 2495-2504.
40. SCHWEITZER, B.I., SRIMATKANDADA, S., GRITSMAN, H., SHERIDAN, R., VENKATARAGHAVAN, R., and BERTINO, J.R. (1989). Probing the role of two hydrophobic site residues in the human dihydrofolate reductase by site-directed mutagenesis. J. Biol. Chem. 264, 20786-20795.
41. SRIMATKANDADA, S., SCHWEITZER, B.I., MOROSON, B.A., DUBE, S., and BERTINO, J.R (1989). Amplification of a polymorphic dihydrofolate reductase gene expressing an enzyme with decreased binding to methotrexate in a human colon carcinoma cell line, HCT-8R4, resistant to this drug. J. Biol. Chem. 264, 3524-3528.
42. SUGIMOTO, Y., AKSENTIJEVICH, I., MURRAY, G.J., BRADY, R.O., PASTAN, I., and GOTTESMAN, M.M. (1995). Retroviral coexpression of a multidrug resistance gene (MDR1) and human β-galactosidase A for gene therapy of Fabry disease. Hum. Gene Ther. 6, 905-915.
43. TAKEBE, N., NAKAHARA, S., ZHAO, S.C., ADHIKARI, D., URAL, A.U., IWAMOTO, M., BANERJEE, D., and BERTINO, J.R. (2000). Comparison of methotrexate resistance conferred by a mutated dihydrofolate reductase (DHFR) cDNA in two different retroviral vectors. Cancer Gene Ther. 7, 920-929.
44. THILLET, J., ABSIL, J., STONE, S.R., and PICTET, R. (1988). Site-directed mutagenesis of mouse dihydrofolate reductase. Mutants with increased resistance to methotrexate and trimethoprim. J. Biol. Chem. 263, 12500-22508.
45. TONG, Y., LIU-CHEN, X., ERCIKAN-ABALI, E.A., CAPIAUX, G.M., BANERJEE, D., and BERTINO, J.R. (1998a). Isolation and Characterization of thymitaq (AG337) and 5-fluoro-2-deoxyuridylate-resistant mutants of human thymidylate synthase from ethyl methanesulfonate-exposed human sarcoma HT1080 cells. J. Biol. Chem. 273, 11611-11618.
46. TONG, Y., LIU-CHEN, X., ERCIKAN-ABALI, E.A., ZHAO, S.C., BANERJEE, D., MALEY, F., and BERTINO, J.R. (1998b). Probing the folate-binding site of human thymidylate synthase by site-directed mutagenesis. J. Biol. Chem. 273, 31209-31214.
47. WAHBA, A.J., and FRIEDKIN, M. (1961). Direct spectrophotometric evidence for the oxidation of tetrahydrofolate during the enzymatic synthesis of thymidylate. J. Biol. Chem. 236, 11-12.
48. UNTCH, M., THOMSSEN, C. STEFFEN, K., KATJA, B., BAUERFEIND, I., OBERLECHNER, E., HARBECK, N., KONECNY, G., and JAENICKE, F. (2002). Five-year results of a randomized multicenter dose intense (DI-EC) study with epirubicin (E) and cyclophosphamide (C) in high risk breast cancer patients - a treatment of short duration with comparable efficacy to conventional chemotherapy. Abstract 641, 25th Annual San Antonio Breast Cancer Symposium.
49. WILLIAMS, D.A., HSIEH, K., DESILVA, A., and MULLIGAN, R.C. (1987). Protection of bone marrow transplant recipients from lethal doses of methotrexate by the generation of methotrexate resistant bone marrow. J. Exp. Med. 166, 210-218.
50. WILLIAMS, J.W. and MORRISON, J.F. (1979). The kinetics of reversible tight binding inhibition. Methods Enzymol. 63, 437-467.
51. WILLIAMS, J.W., MORRISON, J.F., and DUGGLEBY, R.G. (1979). Methotrexate, a high affinity pseudosubstrate of dihydrofolate reductase. Biochemistry 18, 2567-2573.
52. YALOWICH, J.C., and KALMAN, T.I. (1985). Rapid determination of thymidylate synthase activity and its inhibition in intact L1210 leukemia cells in vitro. Biochem. Pharmacol. 34, 2319-2324.
53. ZHAO, S.C., LI, M.X., BANERJEE, D., SCHWEITZER, B.I., MINEISHI, S., GILBOA, E., and BERTINO, J.R. (1994). Long-term protection of recipient mice from lethal doses of methotrexate by marrow infected with a double-copy vector retrovirus containing a mutant dihydrofolate reductase. Cancer Gene Ther. 1, 27-33.